Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.
Br J Clin Pharmacol
; 88(12): 5238-5256, 2022 12.
Article
in En
| MEDLINE
| ID: mdl-35655123
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Esterases
/
Histone Deacetylase Inhibitors
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Br J Clin Pharmacol
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: